TJPC(SH:600488)2023-08-29 09:08Group 1: Company Overview and Event Participation - Tianjin Pharmaceutical Co., Ltd. participated in the 2023 Annual Tianjin Listed Companies Half-Year Report Performance Briefing on September 5, 2023 [2][3] - The event was organized by Tianjin Securities Regulatory Bureau, Tianjin Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [2] Group 2: Financial Performance and R&D Investment - In the first half of 2023, the company's R&D expenses amounted to approximately CNY 84.93 million, representing a year-on-year increase of 23.10% [4] - The company's revenue from steroid hormone business reached CNY 1.086 billion, with a year-on-year growth of 17.98% [9] Group 3: Market Presence and Product Strategy - The company has established a strong international market presence, with raw material drug sales covering over 70 countries and regions [5][9] - The company aims to expand its global vision and focus on high-end markets in Europe and America while accelerating the international registration of new products in emerging markets [5] Group 4: Product Portfolio and Market Share - Major products include over 40 types of steroid hormone raw materials and 23 types of amino acid raw materials, with several achieving over CNY 100 million in sales in 2022 [11] - The company’s prednisone tablets ranked first in market share in the U.S. for two consecutive years (2021-2022) [7][8] Group 5: Cash Flow and Financial Health - The net cash flow from operating activities exceeded CNY 313 million in the first half of 2023, reflecting a year-on-year increase of 39.52% [15]